Ping An Shareholders Approve 40x Authorized Share Increase and Price-Triggered Further Consolidations
PASW sits 67% above its 52-week low of $3.07 on light trading volume (0.4× avg).
Summary
Ping An Biomedical shareholders ratified the 1-for-40 reverse split and approved a 40x increase in authorized share capital plus standing authority for further price-triggered consolidations. The new authorized shares give the company room to issue against its $300 million shelf without another vote.
Key Events · Financing and Capital Events · PASW
-
Authorized Capital Raised 40x
Authorized capital rises from US$312,500 to US$12,500,000, creating 4,777,500,000 new authorized Class A shares and 97,500,000 Class B shares at US$0.0025 par.
-
Room to Issue Against $300M Shelf
The enlarged authorization removes the need for a shareholder vote before issuing shares under the universal shelf registered on 2026-10-23.
-
Price-Triggered Further Consolidations Approved
The board can consolidate at 10:1, 20:1, 50:1 or 80:1 if the Class A price closes below US$1.00 for 20 consecutive trading days (5 days for the 80:1 trigger), effective the 21st (or 6th) trading day.
-
Reverse Split Ratified
The already-executed 1-for-40 consolidation effective 2026-10-23 was ratified with 1,294,500,069 votes for and 30,150 against; 112,867,000 Class A and 12,250,000 Class B shares were outstanding at the September 29 record date.
Analysis · PASW · Manufacturing
The reverse split ratification is old news, but the other approvals matter. Authorized capital jumps from US$312,500 to US$12,500,000, creating 4,777,500,000 new authorized Class A shares at US$0.0025 par — roughly 40x the current authorized base. That is the legal headroom for the $300 million shelf filed 2026-10-23, so future issuance no longer needs a shareholder vote. Shareholders also handed the board standing authority to consolidate again at 10:1, 20:1, 50:1 or 80:1 if the Class A price falls below US$1.00 for 20 consecutive trading days (5 days for the 80:1 trigger). That is a pre-authorized defense against a Nasdaq minimum-bid deficiency, and it tells you management expects the price could slide back under US$1.00. Against a backdrop of a previously disclosed delisting risk and a fresh auditor change, this is a company arming itself to raise equity and stay listed.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.5% of the 1545 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASW was trading at $5.12 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $14.4M. The 52-week trading range was $3.07 to $30.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.